CMV
Analysis of gMDSC frequencies in CHB cohorts a) PBMC from a small cohort of patients with CHB and healthy controls were stained for CD33, CD11b, HLA-DR, CD14 and CD15 and analyzed for gMDSC frequencies (as shown in Fig. 1a ) when freshly isolated (upper-panel) or post-freezing (lower-panel) in FBS supplemented with 10% DMSO (24hr, -80 °C; comparison sample plots, paired frequencies, and correlation between frequencies). b) Representative FACS plot depicting co-expression of CD16 and CD66b on gMDSC. c) Haematoxylin-eosin staining of flow cytometric-isolated gMDSC. d) Absolute number of gMDSC, assessed using BD-TruCount tubes from whole, heparinised blood (n = 11, healthy controls; n = 13, CHB). e) gMDSC frequencies from isolated PBMC samples collected in the two different anti-coagulants, EDTA or heparin (n = 1, healthy control; n = 4, CHB) and cumulative data from the study cohorts, one collected in EDTA (n = 55, healthy controls; n = 54, CHB) and the other in heparin (n = 44, healthy controls; n = 84, CHB). Cross-sectional analysis of study participants, gMDSC frequencies were classified (where relevant) by: f) age (years), g) CMV serostatus, h) HBV viral load (IU/ml), i) circulating HBsAg (IU/ml) and j) presence of HBeAg. Error bars represent the mean ± SEM for the cohorts indicated; * p<0.05; ** p<0.01; *** p<0.001; a, e paired t test; d, g, j unpaired t test; a, f, h-i Pearson product-moment correlation coefficient; e one way ANOVA (Tukey's multiple comparisons test). + T cells (identified using HLA-A2 restricted dextramers, described in Online Methods), d) HBV-and CMV-specific CD8 + T cells (n = 7, CHB) and e) global and CMV-specific CD8 + T cells (n = 10, CHB). Error bars represent the mean ± SEM for the cohorts indicated; * p<0.05; ** p<0.01; *** p<0.001; a unpaired t test, b-e paired t test. n/a n/a n/a n/a * CHB = subjects with chronic hepatitis B; ALT = serum alanine transaminase; blq = below the level of quantification; n/a = not applicable
